SWOG/ Support |
STUDY | R E G |
O P E N |
ARM | ACCR. GOAL |
TOTAL REGS. |
REGS. LAST 12 Month |
REGS. LAST 6 Month |
REGS. LAST 3 Month |
REGS. LAST 30 DAYS |
REGS. LAST 7 DAYS |
DATE OF FIRST REG. |
# of ACT. INSTs |
# of CURR IRBs |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
SWOG | S1007-Breast,Adj,N1,Endocrine+/-Chemo | 1 | N | 1 Recurrence Score testing | 9400 | 148 | 0 | 0 | 0 | 0 | 0 | 02/28/2011 | 458 | 188 |
148 | 0 | 0 | 0 | 0 | 0 | |||||||||
2 | N | 2 Chemo and Endocrine Therapy | 5000 | 48 | 0 | 0 | 0 | 0 | 0 | 02/28/2011 | ||||
3 Endocrine Therapy Alone | 59 | 0 | 0 | 0 | 0 | 0 | ||||||||
107 | 0 | 0 | 0 | 0 | 0 | |||||||||
S1316-Compar. Effectiv. Trial for MBO | 1 | N | 1 Randomization Surgery | 220 | 10 | 0 | 0 | 0 | 0 | 0 | 05/11/2015 | |||
2 Randomization Non-surgical Management | 6 | 0 | 0 | 0 | 0 | 0 | ||||||||
16 | 0 | 0 | 0 | 0 | 0 | |||||||||
S1703-Met Breast, STM-monitoring v Usual Care | 1 | Y | 0 Screening | 739 | 12 | 12 | 12 | 10 | 1 | 0 | 09/17/2018 | 208 | 89 | |
12 | 12 | 12 | 10 | 1 | 0 | |||||||||
2 | Y | 1 Control (Usual Care) | 739 | 1 | 1 | 1 | 0 | 0 | 0 | 09/17/2018 | ||||
1 | 1 | 1 | 0 | 0 | 0 | |||||||||
S1714-CIPN Risk Prediction Cohort Study, Taxanes | 1 | N | 1 Observation | 1050 | 80 | 0 | 0 | 0 | 0 | 0 | 05/14/2019 | 5 | 1 | |
80 | 0 | 0 | 0 | 0 | 0 | |||||||||
S1802-Pros, Stg IV, SST ± Surg/RT to Primary Tum | 1 | Y | 0 Induction SST | 1273 | 29 | 25 | 16 | 3 | 0 | 0 | 09/24/2018 | 348 | 143 | |
29 | 25 | 16 | 3 | 0 | 0 | |||||||||
2 | Y | 1 Standard Systemic Therapy Only | 1273 | 6 | 6 | 6 | 4 | 1 | 0 | 09/24/2018 | ||||
2 SST + Surgery/RT | 9 | 9 | 8 | 4 | 0 | 0 | ||||||||
15 | 15 | 14 | 8 | 1 | 0 | |||||||||
S1827-SCLC, MRI Surveillance +/- PCI | 1 | Y | 1 PCI + MRI brain surveillance | 668 | 4 | 2 | 0 | 0 | 0 | 0 | 05/04/2020 | 343 | 129 | |
2 MRI brain surveillance | 1 | 1 | 0 | 0 | 0 | 0 | ||||||||
5 | 3 | 0 | 0 | 0 | 0 | |||||||||
S2010-ASPEN: Brst, Stg I-III, ASM vs Pt Ed | 1 | Y | 1 Active Symptom Monitoring + Patient Education | 540 | 18 | 14 | 10 | 8 | 3 | 0 | 03/29/2023 | 231 | 106 | |
2 Patient Education | 24 | 16 | 7 | 5 | 5 | 0 | ||||||||
42 | 30 | 17 | 13 | 8 | 0 | |||||||||
S2013-I-CHECKIT: ICI toxicity risk prediction study | 1 | Y | 1 Observation Arm | 3609 | 44 | 28 | 0 | 0 | 0 | 0 | 09/13/2021 | 212 | 115 | |
44 | 28 | 0 | 0 | 0 | 0 | |||||||||
S0702-Zoledronic Acid ONJ Registry | 1 | N | 1 Observation for ONJ | 3500 | 57 | 0 | 0 | 0 | 0 | 0 | 01/30/2009 | |||
57 | 0 | 0 | 0 | 0 | 0 | |||||||||
S0819-NSCLC, ADV, CHEMO/BEV +/-CET | 1 | N | 1 Chemo+/-Bev w/o Cetuximab | 1700 | 1 | 0 | 0 | 0 | 0 | 0 | 08/13/2009 | |||
2 Chemo+/-Bev w/ Cetuximab | 1 | 0 | 0 | 0 | 0 | 0 | ||||||||
2 | 0 | 0 | 0 | 0 | 0 | |||||||||
No | EA1151-Prev, Tomosynthesis Mammographic Screening | 1 | E | Total Registrations | 71 | 71 | 71 | 71 | 33 | 5 | 01/30/2018 | 237 | 97 | |
71 | 71 | 71 | 71 | 33 | 5 | |||||||||
SWOG/ Support |
STUDY | R E G |
O P E N |
ARM | ACCR. GOAL |
TOTAL REGS. |
REGS. LAST 12 Month |
REGS. LAST 6 Month |
REGS. LAST 3 Month |
REGS. LAST 30 DAYS |
REGS. LAST 7 DAYS |
DATE OF FIRST REG. |
# of ACT. INSTs |
# of CURR IRBs |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
SWOG | S1007-Breast,Adj,N1,Endocrine+/-Chemo | 1 | N | 1 Recurrence Score testing | 9400 | 132 | 0 | 0 | 0 | 0 | 0 | 02/28/2011 | 458 | 188 |
132 | 0 | 0 | 0 | 0 | 0 | |||||||||
2 | N | 2 Chemo and Endocrine Therapy | 5000 | 44 | 0 | 0 | 0 | 0 | 0 | 02/28/2011 | ||||
3 Endocrine Therapy Alone | 52 | 0 | 0 | 0 | 0 | 0 | ||||||||
96 | 0 | 0 | 0 | 0 | 0 | |||||||||
S1316-Compar. Effectiv. Trial for MBO | 1 | N | 1 Randomization Surgery | 220 | 5 | 0 | 0 | 0 | 0 | 0 | 05/11/2015 | |||
2 Randomization Non-surgical Management | 3 | 0 | 0 | 0 | 0 | 0 | ||||||||
8 | 0 | 0 | 0 | 0 | 0 | |||||||||
S1714-CIPN Risk Prediction Cohort Study, Taxanes | 1 | N | 1 Observation | 1050 | 60 | 0 | 0 | 0 | 0 | 0 | 05/14/2019 | 5 | 1 | |
60 | 0 | 0 | 0 | 0 | 0 | |||||||||
S1802-Pros, Stg IV, SST ± Surg/RT to Primary Tum | 1 | Y | 0 Induction SST | 1273 | 20 | 19 | 13 | 2 | 0 | 0 | 09/24/2018 | 348 | 143 | |
20 | 19 | 13 | 2 | 0 | 0 | |||||||||
2 | Y | 1 Standard Systemic Therapy Only | 1273 | 6 | 6 | 6 | 4 | 1 | 0 | 09/24/2018 | ||||
2 SST + Surgery/RT | 6 | 6 | 6 | 3 | 0 | 0 | ||||||||
12 | 12 | 12 | 7 | 1 | 0 | |||||||||
S1827-SCLC, MRI Surveillance +/- PCI | 1 | Y | 1 PCI + MRI brain surveillance | 668 | 4 | 2 | 0 | 0 | 0 | 0 | 05/04/2020 | 343 | 129 | |
2 MRI brain surveillance | 1 | 1 | 0 | 0 | 0 | 0 | ||||||||
5 | 3 | 0 | 0 | 0 | 0 | |||||||||
S2010-ASPEN: Brst, Stg I-III, ASM vs Pt Ed | 1 | Y | 1 Active Symptom Monitoring + Patient Education | 540 | 9 | 9 | 8 | 7 | 2 | 0 | 03/29/2023 | 231 | 106 | |
2 Patient Education | 5 | 5 | 3 | 2 | 2 | 0 | ||||||||
14 | 14 | 11 | 9 | 4 | 0 | |||||||||
S2013-I-CHECKIT: ICI toxicity risk prediction study | 1 | Y | 1 Observation Arm | 3609 | 13 | 13 | 0 | 0 | 0 | 0 | 09/13/2021 | 212 | 115 | |
13 | 13 | 0 | 0 | 0 | 0 | |||||||||
S0702-Zoledronic Acid ONJ Registry | 1 | N | 1 Observation for ONJ | 3500 | 57 | 0 | 0 | 0 | 0 | 0 | 01/30/2009 | |||
57 | 0 | 0 | 0 | 0 | 0 | |||||||||
S0819-NSCLC, ADV, CHEMO/BEV +/-CET | 1 | N | 1 Chemo+/-Bev w/o Cetuximab | 1700 | 1 | 0 | 0 | 0 | 0 | 0 | 08/13/2009 | |||
2 Chemo+/-Bev w/ Cetuximab | 1 | 0 | 0 | 0 | 0 | 0 | ||||||||
2 | 0 | 0 | 0 | 0 | 0 | |||||||||
SWOG/ Support |
STUDY | R E G |
O P E N |
ARM | ACCR. GOAL |
TOTAL REGS. |
REGS. LAST 12 Month |
REGS. LAST 6 Month |
REGS. LAST 3 Month |
REGS. LAST 30 DAYS |
REGS. LAST 7 DAYS |
DATE OF FIRST REG. |
# of ACT. INSTs |
# of CURR IRBs |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
SWOG | S1007-Breast,Adj,N1,Endocrine+/-Chemo | 1 | N | 1 Recurrence Score testing | 9400 | 16 | 0 | 0 | 0 | 0 | 0 | 02/28/2011 | 458 | 188 |
16 | 0 | 0 | 0 | 0 | 0 | |||||||||
2 | N | 2 Chemo and Endocrine Therapy | 5000 | 4 | 0 | 0 | 0 | 0 | 0 | 02/28/2011 | ||||
3 Endocrine Therapy Alone | 7 | 0 | 0 | 0 | 0 | 0 | ||||||||
11 | 0 | 0 | 0 | 0 | 0 | |||||||||
S1316-Compar. Effectiv. Trial for MBO | 1 | N | 2 Randomization Non-surgical Management | 220 | 1 | 0 | 0 | 0 | 0 | 0 | 05/11/2015 | |||
1 | 0 | 0 | 0 | 0 | 0 | |||||||||
S1714-CIPN Risk Prediction Cohort Study, Taxanes | 1 | N | 1 Observation | 1050 | 10 | 0 | 0 | 0 | 0 | 0 | 05/14/2019 | 5 | 1 | |
10 | 0 | 0 | 0 | 0 | 0 | |||||||||
S1802-Pros, Stg IV, SST ± Surg/RT to Primary Tum | 1 | Y | 0 Induction SST | 1273 | 4 | 3 | 1 | 0 | 0 | 0 | 09/24/2018 | 348 | 143 | |
4 | 3 | 1 | 0 | 0 | 0 | |||||||||
2 | Y | 2 SST + Surgery/RT | 1273 | 1 | 1 | 1 | 1 | 0 | 0 | 09/24/2018 | ||||
1 | 1 | 1 | 1 | 0 | 0 | |||||||||
SWOG/ Support |
STUDY | R E G |
O P E N |
ARM | ACCR. GOAL |
TOTAL REGS. |
REGS. LAST 12 Month |
REGS. LAST 6 Month |
REGS. LAST 3 Month |
REGS. LAST 30 DAYS |
REGS. LAST 7 DAYS |
DATE OF FIRST REG. |
# of ACT. INSTs |
# of CURR IRBs |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
SWOG | S1316-Compar. Effectiv. Trial for MBO | 1 | N | 1 Randomization Surgery | 220 | 5 | 0 | 0 | 0 | 0 | 0 | 05/11/2015 | ||
2 Randomization Non-surgical Management | 2 | 0 | 0 | 0 | 0 | 0 | ||||||||
7 | 0 | 0 | 0 | 0 | 0 | |||||||||
S1703-Met Breast, STM-monitoring v Usual Care | 1 | Y | 0 Screening | 739 | 10 | 10 | 10 | 9 | 0 | 0 | 09/17/2018 | 208 | 89 | |
10 | 10 | 10 | 9 | 0 | 0 | |||||||||
S2010-ASPEN: Brst, Stg I-III, ASM vs Pt Ed | 1 | Y | 1 Active Symptom Monitoring + Patient Education | 540 | 8 | 4 | 1 | 1 | 1 | 0 | 03/29/2023 | 231 | 106 | |
2 Patient Education | 16 | 8 | 4 | 3 | 3 | 0 | ||||||||
24 | 12 | 5 | 4 | 4 | 0 | |||||||||
SWOG/ Support |
STUDY | R E G |
O P E N |
ARM | ACCR. GOAL |
TOTAL REGS. |
REGS. LAST 12 Month |
REGS. LAST 6 Month |
REGS. LAST 3 Month |
REGS. LAST 30 DAYS |
REGS. LAST 7 DAYS |
DATE OF FIRST REG. |
# of ACT. INSTs |
# of CURR IRBs |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
SWOG | S1714-CIPN Risk Prediction Cohort Study, Taxanes | 1 | N | 1 Observation | 1050 | 10 | 0 | 0 | 0 | 0 | 0 | 05/14/2019 | 5 | 1 |
10 | 0 | 0 | 0 | 0 | 0 | |||||||||
S1802-Pros, Stg IV, SST ± Surg/RT to Primary Tum | 1 | Y | 0 Induction SST | 1273 | 5 | 3 | 2 | 1 | 0 | 0 | 09/24/2018 | 348 | 143 | |
5 | 3 | 2 | 1 | 0 | 0 | |||||||||
2 | Y | 2 SST + Surgery/RT | 1273 | 2 | 2 | 1 | 0 | 0 | 0 | 09/24/2018 | ||||
2 | 2 | 1 | 0 | 0 | 0 | |||||||||
S2013-I-CHECKIT: ICI toxicity risk prediction study | 1 | Y | 1 Observation Arm | 3609 | 9 | 5 | 0 | 0 | 0 | 0 | 09/13/2021 | 212 | 115 | |
9 | 5 | 0 | 0 | 0 | 0 | |||||||||
No | EA1151-Prev, Tomosynthesis Mammographic Screening | 1 | E | Total Registrations | 71 | 71 | 71 | 71 | 33 | 5 | 01/30/2018 | 237 | 97 | |
71 | 71 | 71 | 71 | 33 | 5 | |||||||||
SWOG/ Support |
STUDY | R E G |
O P E N |
ARM | ACCR. GOAL |
TOTAL REGS. |
REGS. LAST 12 Month |
REGS. LAST 6 Month |
REGS. LAST 3 Month |
REGS. LAST 30 DAYS |
REGS. LAST 7 DAYS |
DATE OF FIRST REG. |
# of ACT. INSTs |
# of CURR IRBs |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
SWOG | S1703-Met Breast, STM-monitoring v Usual Care | 1 | Y | 0 Screening | 739 | 2 | 2 | 2 | 1 | 1 | 0 | 09/17/2018 | 208 | 89 |
2 | 2 | 2 | 1 | 1 | 0 | |||||||||
2 | Y | 1 Control (Usual Care) | 739 | 1 | 1 | 1 | 0 | 0 | 0 | 09/17/2018 | ||||
1 | 1 | 1 | 0 | 0 | 0 | |||||||||
S2010-ASPEN: Brst, Stg I-III, ASM vs Pt Ed | 1 | Y | 1 Active Symptom Monitoring + Patient Education | 540 | 1 | 1 | 1 | 0 | 0 | 0 | 03/29/2023 | 231 | 106 | |
2 Patient Education | 3 | 3 | 0 | 0 | 0 | 0 | ||||||||
4 | 4 | 1 | 0 | 0 | 0 | |||||||||
S2013-I-CHECKIT: ICI toxicity risk prediction study | 1 | Y | 1 Observation Arm | 3609 | 22 | 10 | 0 | 0 | 0 | 0 | 09/13/2021 | 212 | 115 | |
22 | 10 | 0 | 0 | 0 | 0 | |||||||||